New imaging tracer could sharpen detection of aggressive breast cancer

NCT ID NCT01093612

Ongoing Diagnosis Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests a special PET scan using a radioactive tracer called 64Cu-DOTA-trastuzumab in 18 women with advanced HER2-positive breast cancer. The goal is to see if this scan can better identify HER2-positive tumors compared to standard imaging. If it works, it may help doctors choose more targeted treatments for each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: copper Cu 64-DOTA-trastuzumab (a radioactive tracer for PET scans)
What this could lead to: If successful, this imaging method could help doctors more accurately identify HER2-positive tumors and plan better treatments for advanced breast cancer.
What could go wrong: This is a very small pilot study with only 18 participants, so results may not apply to all patients. The technique is still experimental and not yet proven to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER STAGE IV BREAST CANCER

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.